In addition, MIF exhibits an endogenous counter-regulation of the anti-inflammatory effects of GCs [14–16] and leads to a potentially decreased response to GC-treatment in autoimmune diseases [17–20]. The gene discussed is MIF; the disease is autoimmune disease.